Tech Transfer Central

Expert Strategies for Patenting and Licensing Early-Stage Drug Discoveries

Format: On-Demand Video/Transcript, or DVD
Originally presented: Tuesday, November 9, 2021
Price: $197
order button view cart

Universities and academic institutions are devoting tens of millions of research dollars toward drug discovery activity with no sign of a slowdown, and biopharma companies are increasingly relying on academia to fill their pipelines. Some universities have established their own drug development programs to de-risk their innovations and take them further toward commercialization, but for most schools the cost and risk involved is too high, and the development timeline is too long.

The most common commercialization approach is to file a patent application on an early-stage compound or drug candidate, claiming the novel and inventive aspects of the discovery, and then seek to license the early-stage asset to a commercial partner for further development.

Though it’s the more common pathway for universities and their TTOs, it’s far from a routine exercise, and rushing the process can be detrimental – if not catastrophic. Without a firm understanding of the criteria for patentability, essential claims language, data requirements, and how sponsored research and research partnerships come into play, your entire investment and your researchers’ years of hard work could go up in the smoke of invalidity challenges or licensee disinterest.

That’s why Tech Transfer Central’s Distance Learning Division is teaming up with Lisa Mueller, a patent attorney with deep experience in biopharma patent law and licensing, for this critically important webinar:

Early-Stage Drug Discoveries

Ms. Mueller will explore in detail patent strategies in academic drug discovery. Specifically, the criteria for patentability, including the patenting of salts, solvates, polymorphs and prodrugs as well as drug repurposing. Topics to be discussed include:

  • What can be patented?
  • Criteria for patenting drug discoveries
  • What data is needed and when is it due by?
  • Assuring novelty and anticipating invalidity challenges
  • Strategies for maximizing protection of your discoveries
  • Patents and repurposed drugs
  • Methods for attracting licensees
  • De-risking for greater marketability
  • How stage of discovery affects licensing terms

Meet your session leader:

Lisa L. Mueller
Patent attorney
Casimir Jones

Ms. Mueller has over 28 years of experience providing strategic counsel on complex patent issues to clients in the plant, food, pharmaceutical, biopharmaceutical, biotechnology and chemistry sectors. She is a trusted advisor to both university, corporate and start-up clients and brings an in-depth knowledge and extensive experience to her work advising clients on the global patent protection, freedom to operate and validity of the products that they aim to produce and distribute. A thought leader on life science patent law, Ms. Mueller speaks frequently to legal and industry groups and publishes widely.

She is the author of the blog BRICS & Beyond, which provides unique insights on patent law developments in the life sciences industry not only in Brazil, Russia, India and China, but in other countries outside of the United States.  She is also the host of the podcast Tech Transfer IP, which interviews the leaders in Technology Transfer.

Our Guarantee of Quality and Value

We stand 100% behind the quality and value of our products. If you are dissatisfied, simply let us know and we will send you an immediate refund for your entire order -- no questions asked.

order button
view cart

Click here for a printable order form